2-NBDG Fluorescence Imaging of Hypermetabolic Circulating Tumor Cells in Mouse Xenograft model of Breast Cancer

ObjectivesTo determine use of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG) as a tracer for detection of hypermetabolic circulating tumor cells (CTC) by fluorescence imaging.ProceduresHuman breast cancer cells were implanted in the mammary gland fat pad of athymic mice to establish orthotopic human breast cancer xenografts as a mouse model of circulating breast cancer cells. Near-infrared fluorescence imaging of the tumor-bearing mice injected with 2-DeoxyGlucosone 750 (2-DG 750) was conducted to assess glucose metabolism of xenograft tumors. Following incubation with fluorescent 2-NBDG, circulating breast cancer cells in the blood samples collected from the tumor-bearing mice were collected by magnetic separation, followed by fluorescence imaging for 2-NBDG uptake by circulating breast cancer cells, and correlation of the number of hypermetabolic circulating breast cancer cells with tumor size at the time when the blood samples were collected.ResultsHuman breast cancer xenograft tumors derived from MDA-MB-231, BT474, or SKBR-3 cells were visualized on near-infrared fluorescence imaging of the tumor-bearing mice injected with 2-DG 750. Hypermetabolic circulating breast cancer cells with increased uptake of fluorescent 2-NBDG were detected in the blood samples from tumor-bearing mice and visualized by fluorescence imaging, but not in the blood samples from normal control mice. The number of hypermetabolic circulating breast cancer cells increased along with growth of xenograft tumors, with the number of hypermetabolic circulating breast cancer cells detected in the mice bearing MDA-MB231 xenografts larger than those in the mice bearing BT474 or SKBR-3 xenograft tumors.ConclusionsCirculating breast cancer cells with increased uptake of fluorescent 2-NBDG were detected in mice bearing human breast cancer xenograft tumors by fluorescence imaging, suggesting clinical use of 2-NBDG as a tracer for fluorescence imaging of hypermetabolic circulating breast cancer cells.

[1]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Timothy J. Muldoon,et al.  Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy‐glucose , 2009, International journal of cancer.

[3]  K. Pantel,et al.  Clinical relevance and biology of circulating tumor cells , 2011, Breast Cancer Research.

[4]  Eva Sevick-Muraca,et al.  Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. , 2009, Analytical Biochemistry.

[5]  James N Ingle,et al.  Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. Heusser,et al.  Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies , 2012, BMC Cancer.

[7]  K. Hunt,et al.  Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue , 2011, Biomedical optics express.

[8]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[9]  H. Abé,et al.  Intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in Escherichia coli cells. , 1996, Bioscience, biotechnology, and biochemistry.

[10]  M. Shenkin,et al.  Accurate assessment of cell count and viability with a flow cytometer , 2007, Cytometry. Part B, Clinical cytometry.

[11]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Nizar Mullani,et al.  Uptake of a Fluorescent Deoxyglucose Analog (2-NBDG) in Tumor Cells , 2005, Molecular Imaging and Biology.

[13]  Z. Shen,et al.  2-NBDG as a fluorescent indicator for direct glucose uptake measurement. , 2005, Journal of biochemical and biophysical methods.

[14]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[15]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[16]  Giovanna Bises,et al.  Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients , 2011, Acta oncologica.

[17]  Hideaki Matsuoka,et al.  A real-time method of imaging glucose uptake in single, living mammalian cells , 2007, Nature Protocols.

[18]  F. Solé,et al.  Biomarkers characterization of circulating tumour cells in breast cancer patients , 2012, Breast Cancer Research.

[19]  W. Bolton,et al.  Comparison of cell viability probes compatible with fixation and permeabilization for combined surface and intracellular staining in flow cytometry. , 1995, Cytometry.

[20]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[21]  N. Meyer,et al.  Annexin V/7-AAD staining in keratinocytes. , 2011, Methods in molecular biology.

[22]  Gyan Bhanot,et al.  Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines , 2012, PloS one.

[23]  G. Dontu,et al.  Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. , 2008, Cancer research.

[24]  Volker Budach,et al.  A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[25]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[26]  Zhen Cheng,et al.  Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. , 2006, Bioconjugate chemistry.

[27]  K. Oh,et al.  A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. , 1996, Biochimica et biophysica acta.

[28]  J S Fowler,et al.  A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Wei Liu,et al.  Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry , 2012, Tumor Biology.

[30]  H. Biersack,et al.  FDG-PET in monitoring therapy of breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[32]  I Schmid,et al.  Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. , 1992, Cytometry.

[33]  Sepp Kaul,et al.  Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine , 2012, Breast Care.

[34]  Julie H. Ostrander,et al.  Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines , 2011, Breast Cancer Research and Treatment.

[35]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.